Real-World watch on ph+ leukemia treatments aims to uncover best paths to remission
NCT ID NCT07684131
First seen Jul 06, 2026 · Last updated Jul 07, 2026 · Updated 1 time
Summary
This study follows adults aged 18 and older who have a specific type of acute lymphoblastic leukemia (Ph+ ALL) and are receiving a combination of targeted drugs (BCR::ABL1 inhibitors) along with chemotherapy, steroids, or antibody therapy. Researchers will track how long patients live and how well the cancer responds over 12 to 36 months. The goal is to gather real-world data on the effectiveness of these treatment combinations.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If successful, this observatory could reveal which treatment combinations work best for Ph+ ALL, guiding future care.
- What could go wrong
- This is an observational study, not a controlled trial, so it cannot prove cause and effect. Results may not apply to all patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE LYMPHOBLASTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
CH Le Mans
RECRUITINGLe Mans, France
Contact
-
CH St Etienne
NOT_YET_RECRUITINGSaint-Etienne, France
Contact
-
CH Versailles
RECRUITINGLe Chesnay, France
Contact
-
CH de Lyon
NOT_YET_RECRUITINGPierre-Bénite, France
Contact
-
CH de la cote basque
NOT_YET_RECRUITINGBayonne, France
Contact
-
CHRU de Nancy
NOT_YET_RECRUITINGNancy, France
Contact
-
CHU Angers
NOT_YET_RECRUITINGAngers, France
Contact
-
CHU Bordeaux
RECRUITINGBordeaux, France
Contact
-
CHU Sud Réunion
NOT_YET_RECRUITINGLa Réunion, France
Contact
-
CHU clermont ferrand
RECRUITINGClermont-Ferrand, France
Contact
-
CHU de grenoble
NOT_YET_RECRUITINGGrenoble, France
Contact
-
Centre Antoine Lacassagne
NOT_YET_RECRUITINGNice, 06189, France
Contact
-
Centre Hospitalier sud francilien
RECRUITINGCorbeil-Essonnes, France
Contact
-
Chu de Lille
NOT_YET_RECRUITINGLille, France
Contact
-
Groupe hospitalier sud
NOT_YET_RECRUITINGAmiens, France
Contact
-
Hopital Cochin
NOT_YET_RECRUITINGParis, France
Contact
-
Hopital Militaire Percy
NOT_YET_RECRUITINGClamart, France
Contact
-
Hopital St Louis
RECRUITINGParis, France
Contact
-
Hopital de Purpan
NOT_YET_RECRUITINGToulouse, France
Contact
-
Hopital de la conception
NOT_YET_RECRUITINGMarseille, France
Contact
-
Hopital necker
RECRUITINGParis, France
Contact
-
ICANS
NOT_YET_RECRUITINGStrasbourg, France
Contact
-
Institut Paoli Calmettes
NOT_YET_RECRUITINGMarseille, France
Contact
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a diet and exercise program help childhood leukemia survivors live healthier?
- Could bone marrow from deceased donors cure blood cancers?
- Lab-Grown stem cells could speed immune recovery in blood cancer transplants
- New drug cocktail aims to improve remission in older leukemia patients
- Radioactive antibody hones in on cancer cells to boost transplant success
- Suicide Gene-Equipped t cells aim to make stem cell transplants safer